Yazar "Arslan, Ulku Yalcintas" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients
    (Zerbinis Publications, 2015) Bal, Oznur; Arslan, Ulku Yalcintas; Durnali, Ayse; Uyetrk, Ummugul; Demirci, Ayse; Tastekin, Didem; Ekinci, Ahmet
    Purpose: To evaluate the impact of progesterone receptor (PR) status on estrogen receptor (ER)-positive and HER2-negative breast cancer. Methods: A total of 1673 operable breast cancer patients, diagnosed from June 1984 to June 2 Oil were retrospectively reviewed and 400 patients with ER-positive and HER2-negative tumors were identified and evaluated. ER-positive and HER2-negative patients were classified into two groups: group A: ER+/PR-/HER2- And group B : ER+/PR+/HER2- According to PR status. Results: Median follow-up was 14.2 years (range 10.1-18.2). The ratio of postmenopausal patients was significantly higher in group A (68.2%, p=0.015). Grade 1 tumor and stage I disease were significantly higher in group B (15%, p=0.007 and 15%, p=0.005, respectively). Mean overall survival (OS) and disease free survival (DFS) were significantly better in group B (15.3±1.5 years vs 8.7±0.8 years, p=0.032; 10.5±1.6 years vs 5.7±0.5 years, p=0.022) as compared with group A Relative risk for recurrence and death were two-fold higher in group A (p=0.05 and p=0.01, respectively). Conclusion: PR status exerts a significant impact on prognosis ofER+/HER2- breast cancer.
  • Küçük Resim Yok
    Öğe
    Small bowel perforation due to bevacizumab therapy in metastatic colon carcinoma: a case report and review of the literature
    (Kare Publ, 2011) Uyeturk, Ummugul; Oksuzoglu, Berna; Arslan, Ulku Yalcintas; Alkis, Necati
    Bevacizumab is a monoclonal antibody which targets the vascular endothelial growth factor molecule. It is indicated for the treatment of recurrent and metastatic colorectal cancer. A 66-year-old woman was operated with left hemicolectomy who had a tumor in the left colon causing a total obstruction. Her tumor stage was IV (T3N1M1). 5-Fluorouracil, folinic acid,irinotccan and bevacizumab chemotherapy was started to the patient at the forty day of the colon operation. The patient was hospitalized after first administration of the 5th chemotherapy cycle because of febrile neutropenia. Abdominal pain began although the neutrophil count was within the normal ranges. The patient was operated with the diagnosis of acute abdomen. A one centimeter sized perforation was seen at the ilial loop which was 80 cm proximal to the ileocaecal valve. The patient died 8 days after the operation. Although bevacizumab is generally a well-tolerated agent, one must pay attention.